Analyst Research

Report Title Price
Provider: Stock Traders Daily
$20.00
Provider: MacroRisk Analytics/EconomicInvestor
$25.00
Provider: ValuEngine, Inc.
$25.00
Provider: Wright Reports
$75.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Novo Nordisk A/S Receives U.S. FDA Clearance For Insulin Injection Device Novopen Echo


Wednesday, 21 Aug 2013 10:00am EDT 

Novo Nordisk A/S announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for the insulin device NovoPen Echo. This marks the first and only pen device in the U.S. with half-unit dosing and a memory function that records the dose and time passed since the last injection. This pen is the latest insulin delivery system from Novo Nordisk, and will be available to patients for use with NovoLog (insulin as part [rDNA origin] injection) PenFill cartridges. 

Company Quote

47.62
-0.78 -1.61%
30 Sep 2014